Phase 2 THA Clinical Trials
71 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 71 trials
Recruiting
Phase 1Phase 2
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Beta-ThalassemiaSickle Cell Disease
National Heart, Lung, and Blood Institute (NHLBI)90 enrolled1 locationNCT07599176
Recruiting
Phase 2
A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea
Functional Hypothalamic Amenorrhea (FHA)
Regeneron Pharmaceuticals34 enrolled6 locationsNCT07235917
Recruiting
Phase 2
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
AlbuminuriaSickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
University of Illinois at Chicago20 enrolled1 locationNCT07175051
Recruiting
Phase 1Phase 2
A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors
Advanced Solid Tumors That Are MTAP Deficient
AstraZeneca334 enrolled20 locationsNCT06130553
Recruiting
Phase 2
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
Graves OrbitopathyGraves OphthalmopathyThyroid Eye Disease (TED)
The First Affiliated Hospital of Xiamen University8 enrolled1 locationNCT07547930
Recruiting
Phase 2
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
GerminomaBasal Ganglia GerminomaDiabetes Insipidus+3 more
Children's Oncology Group240 enrolled109 locationsNCT06368817
Recruiting
Phase 2
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
CatalYm GmbH104 enrolled2 locationsNCT07219459
Recruiting
Phase 1Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
Acute Myeloid LeukemiaRecurrent Myelodysplastic SyndromeRefractory Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center52 enrolled1 locationNCT04128748
Recruiting
Phase 2
Role of Estrogen on Skeletal Outcomes in FHA
Bone DensityFHA (Functional Hypothalamic Amenorrhea)Bone Strength
University of Virginia150 enrolled2 locationsNCT07010146
Recruiting
Phase 2
Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
NSCLC Diagnosed by Histology or CytologyA Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical ResectionOverall Lung Function is Adequate for the Planned Lung Resection+1 more
Zhujiang Hospital46 enrolled1 locationNCT07534033
Recruiting
Phase 1Phase 2
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Beta-Thalassemia
Children's Hospital of Philadelphia12 enrolled1 locationNCT06364774
Recruiting
Phase 2
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
Sickle Cell DiseaseThalassemiaThalassemia (beta)
Memorial Sloan Kettering Cancer Center24 enrolled6 locationsNCT05736419
Recruiting
Phase 1Phase 2
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Refractory Acute Myeloid LeukemiaBlasts More Than 5 Percent of Bone Marrow Nucleated CellsPersistent Disease
Ohio State University Comprehensive Cancer Center28 enrolled2 locationsNCT04049539
Recruiting
Phase 2
Ketamine for Methamphetamine Use Disorder
methamphetamine abuseSubstance Use DisordersSubstance Use
University of Texas Southwestern Medical Center120 enrolled5 locationsNCT06496750
Recruiting
Phase 2
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Regeneron Pharmaceuticals95 enrolled26 locationsNCT06421636
Recruiting
Phase 2
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Thalassemia
Kind Pharmaceuticals LLC64 enrolled5 locationsNCT06302491
Recruiting
Phase 2
Feasibility of Long-term, High-dose Stimulant for Methamphetamine Use Disorder
methamphetamine abuseSubstance AbuseMethamphetamine Dependence+2 more
Centre hospitalier de l'Université de Montréal (CHUM)80 enrolled1 locationNCT06788587
Recruiting
Phase 2
Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users
methamphetamine abuseMethamphetamine DependenceAddiction+1 more
Centre hospitalier de l'Université de Montréal (CHUM)440 enrolled4 locationsNCT05854667
Recruiting
Phase 2Phase 3
Divided or Single Exposure (DOSE) Study
Chronic PainOpioid-use DisorderMethadone
University of Maryland, Baltimore150 enrolled1 locationNCT05459402
Recruiting
Phase 2Phase 3
Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo
Post-aggressive ImmunosuppressionAdult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C
Assistance Publique - Hôpitaux de Paris170 enrolled2 locationsNCT06694740